View Older Stories View More Recent Stories
-
Off Wall Street New Strong Sell on iRhythm Technologies (IRTC)
-
Morgan Stanley on iRhythm Technologies (IRTC): 'Solid pre-announce'
-
iRhythm expects 2025 revenue to exceed $740 million guidance
-
iRhythm study shows Zio monitors perform similarly in Asian patients
-
iRhythm Technologies (IRTC) PT Raised to $220 at Freedom Capital Markets
-
iRhythm Technologies (IRTC) PT Raised to $244 at Needham
-
iRhythm Technologies (IRTC) PT Raised to $215 at BTIG
-
iRhythm Technologies (IRTC) PT Raised to $212 at Canaccord Genuity
-
iRhythm Technologies (IRTC) Tops Q3 EPS by 38c, provides guidance
-
Freedom Capital Markets Starts iRhythm Technologies (IRTC) at Buy
-
iRhythm Technologies (IRTC) PT Raised to $193 at Canaccord Genuity
-
Evercore ISI Starts iRhythm Technologies (IRTC) at In Line
-
BofA Securities Starts iRhythm Technologies (IRTC) at Buy
-
iRhythm Technologies (IRTC) Mentioned as Short at Spruce Point
-
iRhythm Technologies (IRTC) PT Raised to $175 at Oppenheimer
-
iRhythm Technologies (IRTC) PT Raised to $180 at Needham
-
iRhythm Technologies (IRTC) Tops Q2 EPS by 19c
-
iRhythm Technologies (IRTC) Tops Q2 EPS by 19c, provides guidance
-
iRhythm Technologies (IRTC) announces Board changes
-
Wells Fargo Upgrades iRhythm Technologies (IRTC) to Overweight
-
iRhythm Technologies (IRTC) PT Lowered to $139 at Canaccord Genuity
-
iRhythm Technologies (IRTC) PT Raised to $140 at BTIG
-
iRhythm Technologies (IRTC) Tops Q1 EPS by 1c
-
iRhythm Technologies (IRTC) Tops Q1 EPS by 1c, provides guidance
-
iRhythm Technologies (IRTC) Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection
-
iRhythm Technologies (IRTC) PT Raised to $145 at Truist Following EBITDA/EPS Beat
-
iRhythm Technologies (IRTC) PT Raised to $145 at Truist Securities
-
iRhythm Technologies (IRTC) PT Raised to $138 at Needham
-
iRhythm Technologies (IRTC) PT Raised to $145 at JPMorgan
-
iRhythm Technologies (IRTC) PT Raised to $135 at BTIG
-
iRhythm Technologies (IRTC) PT Raised to $130 at Citi
-
iRhythm Technologies (IRTC) Tops Q4 EPS by 31c; offers guidance
-
iRhythm Technologies (IRTC) Announces Departure of Mojdeh Poul from Board
-
Oppenheimer Reiterates Outperform Rating on iRhythm Technologies (IRTC)
-
iRhythm Technologies (IRTC) PT Raised to $112 at Needham
-
iRhythm Technologies (IRTC) Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
-
iRhythm Technologies (IRTC) PT Raised to $120 at Oppenheimer
-
iRhythm Technologies (IRTC) PT Lowered to $96 at Needham
-
iRhythm Technologies (IRTC) Receives FDA 510(k) Clearance for Design Modifications to Its Zio AT Device
-
iRhythm Technologies (IRTC) Misses Q3 EPS by 68c ; Offers Guidance
-
Oppenheimer Reiterates Outperform Rating on iRhythm Technologies (IRTC)
-
iRhythm Technologies (IRTC) PT Raised to $95 at Truist Securities
-
BTIG Reiterates Buy Rating on iRhythm Technologies (IRTC)
-
iRhythm Technologies (IRTC) Receives FDA 510(k) Clearance
-
iRhythm Technologies (IRTC) PT Lowered to $100 at Baird
-
Goldman Sachs Starts iRhythm Technologies (IRTC) at Neutral
-
iRhythm Technologies (IRTC) PT Raised to $137 at Canaccord Genuity
-
iRhythm Technologies (IRTC) Announces Japanese Regulatory Approval of the Zio ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
-
iRhythm Technologies (IRTC) Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio Monitor
-
iRhythm Technologies (IRTC) Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
